Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Kilitch Drugs (India) Ltd

KILITCH

Kilitch Drugs (India) Ltd

KILITCH
Health CarePharmaceuticals
SmallcapWith a market cap of ₹489 cr, stock is ranked 1,861
High RiskStock is 3.03x as volatile as Nifty
304.502.14% (-6.65)
304.502.14% (-6.65)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹489 cr, stock is ranked 1,861
High RiskStock is 3.03x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹489 cr, stock is ranked 1,861
High RiskStock is 3.03x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
38.872.79—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.276.550.51%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Kilitch Drugs (India) Limited is engaged in the development and operations of pharmaceutical business. The Company's services range from manufacturing to marketing a host of formulations in solid, liquid and parenteral forms.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 12.93%, vs industry avg of 9.03%

Constant Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0.04%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 30.75%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue23.7729.7953.8986.4957.4571.19117.14142.52158.85157.76
Raw Materialssubtract8.9210.5026.4448.3529.8236.2265.4874.5379.08131.62
Power & Fuel Costsubtract0.971.061.111.421.621.572.252.152.43
Employee Costsubtract3.473.384.305.285.695.246.1811.7310.01
Selling & Administrative Expensessubtract5.176.988.1912.5611.5011.1717.8823.5328.24
Operating & Other expensessubtract6.767.275.287.604.289.0111.949.9310.35
Depreciation/Amortizationsubtract10.059.762.042.052.001.992.473.553.353.41
Interest & Other Itemssubtract0.060.160.420.650.940.881.335.086.046.16
Taxes & Other Itemssubtract-0.44-0.430.964.760.771.362.251.564.753.97
EPS-8.46-6.723.822.630.542.424.746.719.227.83
DPS0.000.000.500.500.000.000.000.000.000.00
Payout ratio0.000.000.130.190.000.000.000.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Kilitch Drugs (India) Ltd33.542.79—
Sun Pharmaceutical Industries Ltd45.346.470.75%
Cipla Ltd31.214.800.82%
Torrent Pharmaceuticals Ltd65.3815.800.88%

Price Comparison

Compare KILITCH with any stock or ETF
Compare KILITCH with any stock or ETF
KILITCH
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding69.23%0.00%0.00%0.00%30.76%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

KILITCH has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 20, 2019

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 20, 2019

Cash Dividend

Ex DateEx DateSep 18, 2018

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 18, 2018

Cash Dividend

Ex DateEx DateSep 24, 2012

Special
Special | Div/Share: ₹30.00

Dividend/Share

₹30.00

Ex DateEx Date

Sep 24, 2012

Cash Dividend

Ex DateEx DateAug 18, 2011

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Aug 18, 2011

Cash Dividend

Ex DateEx DateOct 14, 2010

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Oct 14, 2010

News & Opinions
Corporate
Kilitch Drugs (India) announces board meeting date

Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live

3 days agoCapital Market - Live
Corporate
Kilitch Drugs (India) to convene AGM

Kilitch Drugs (India) announced that the 32th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Kilitch Drugs (India) consolidated net profit declines 60.12% in the June 2024 quarter

Net profit of Kilitch Drugs (India) declined 60.12% to Rs 1.34 crore in the quarter ended June 2024 as against Rs 3.36 crore during the previous quarter ended June 2023. Sales declined 8.51% to Rs 33.45 crore in the quarter ended June 2024 as against Rs 36.56 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales33.4536.56 -9 OPM %4.9616.90 - PBDT2.505.24 -52 PBT1.654.53 -64 NP1.343.36 -60 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Kilitch Drugs (India) to conduct board meeting

Kilitch Drugs (India) will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Krebs Biochemicals & Industries Ltd leads gainers in ‘B’ group

3 months agoBusiness Standard

Kilitch Drugs Standalone March 2022 Net Sales at Rs 32.03 crore, up 51.49% Y-o-Y

2 years agoMoneycontrol

Kilitch Drugs commences Rs100 crore new facility expansion plan

2 years agoIndia Infoline

Kilitch Drugs (India) reports standalone net profit of Rs 2.89 crore in the June 2021 quarter

3 years agoBusiness Standard

Kilitch Drugs starts production of Cephalosporin Injectables at Ethiopia Plant; Stock surges 5%

3 years agoIndia Infoline

Kilitch Drugs (India) reports consolidated net profit of Rs 0.71 crore in the March 2021 quarter

3 years agoBusiness Standard